Two Cases of Hand-Foot Syndrome Induced by Sunitinib.
- Author:
Jin Seob JEONG
1
;
Jeong Hyun YUN
;
Seok Jung YOON
;
Wun Jae KIM
;
Ji Yeoun LEE
;
Tae Young YOON
Author Information
1. Department of Dermatology, College of Medicine, Chungbuk National University, Cheongju, Korea. jyl@chungbuk.ac.kr
- Publication Type:Case Report
- Keywords:
Hand-foot syndrome;
Sunitinib;
Tyrosine kinase inhibitor
- MeSH:
Carcinoma, Renal Cell;
Gastrointestinal Stromal Tumors;
Hand-Foot Syndrome;
Indoles;
Phosphotransferases;
Pyrroles;
Tyrosine
- From:Korean Journal of Dermatology
2008;46(9):1236-1239
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sunitinib (SU11248) is a novel orally administered small molecule that inhibits multiple receptor tyrosine kinases so that can block tumor growth and angiogenesis. It was approved on 2006, for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor. Various cutaneous adverse reactions induced by sunitinib have been reported, including hand-foot syndrome. We report two cases of hand-foot syndrome induced by sunitinib for treatment of advanced renal cell carcinoma.
